Final results from Pfizer Inc’s COVID-19 vaccine trial showed its shot had a 95 per cent success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency US authorization within days, it said on Wednesday. The final analysis comes just a week after initial results from the trial showed the vaccine, developed with German partner BioNTech SE, was more than 90 per cent effective. THE MOST VULNERABLEThe distribution of a Pfizer shot is complicated by the need to store it at ultra-cold temperatures of -70 degrees Celsius. The moves were small, however, compared with the jump when Pfizer first announced the vaccine was more than 90 per cent effective on Nov. 9. "With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world," Pfizer’s Bourla said.

Source: dna November 18, 2020 14:37 UTC